Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025)

Neurogene's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $120000.0 for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $120000.0; the TTM value through Dec 2025 reached $120000.0, up 31.87%, while the annual FY2025 figure was $120000.0, 31.87% up from the prior year.
Asset Writedowns and Impairment reached $120000.0 in Q4 2025 per NGNE's latest filing, up from $91000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $120000.0 in Q4 2025 to a low of $91000.0 in Q1 2024.
Average Asset Writedowns and Impairment over 3 years is $103666.7, with a median of $100000.0 recorded in 2023.